Serum chemerin levels are inversely associated with renal function in a general population

Clinical Endocrinology

Volumn 88, Issue 1, 2018, Pages 146-153

  Zylla, Stephanie ^a,b   Rettig, Rainer ^c   Völzke, Henry ^a,b,d   Endlich, Karlhans ^a   Nauck, Matthias ^a,b   Friedrich, Nele ^a,b,e  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^e Research Centre for Prevention and Health   (Denmark)

Author keywords

adipokines; blood circulation; chronic kidney disease; diabetes mellitus; dyslipidaemia; hypertension; obesity

Indexed keywords

CHEMERIN; CREATININE; CYSTATIN C; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; SIGNAL PEPTIDE;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GERMANY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; MALE; METABOLIC SYNDROME X; POPULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINARY EXCRETION; AGED; BLOOD; EPIDEMIOLOGY; GLOMERULUS FILTRATION RATE; MIDDLE AGED;

AGED; CHEMOKINES; CREATININE; CYSTATIN C; FEMALE; GERMANY; GLOMERULAR FILTRATION RATE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METABOLIC SYNDROME; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 85029396354     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13449     Document Type: Article

References (36)

1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260-272.
2. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19-33.
3. Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184-6223.
4. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-985.
5. Mattern A, Zellmann T, Beck-Sickinger AG. Processing, signaling, and physiological function of chemerin. IUBMB Life. 2014;66:19-26.
6. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-4694.
7. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282:28175-28188.
8. Chakaroun R, Raschpichler M, Kloting N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism. 2012;61:706-714.
9. Zylla S, Pietzner M, Kuhn JP, et al. Serum chemerin is associated with inflammatory and metabolic parameters-results of a population-based study. Obesity (Silver Spring). 2017;25(2):468-475.
10. Pfau D, Stepan H, Kratzsch J, et al. Circulating levels of the adipokine chemerin in gestational diabetes mellitus. Horm Res Paediatr. 2010;74:56-61.
11. Pfau D, Bachmann A, Lössner U, et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care. 2010;33:171-173.
12. Rutkowski P, Sledzinski T, Zielinska H, et al. Decrease of serum chemerin concentration in patients with end stage renal disease after successful kidney transplantation. Regul Pept. 2012;173:55-59.
13. Blaszak J, Szolkiewicz M, Sucajtys-Szulc E, et al. High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction. Ren Fail. 2015;37:1033-1038.
14. Hu W, Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract. 2011;91:159-163.
15. Leiherer A, Muendlein A, Kinz E, et al. High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events—insights from phenotype and genotype characterization. Vascul Pharmacol. 2015;77:60-68.
16. Yamamoto T, Qureshi AR, Anderstam B, et al. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant. 2010;25:4017-4023.
17. Völzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40:294-307.
18. Carlson RV, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol. 2004;57:695-713.
19. Report of the National Cholesterol Education Program (NCEP). Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Final Report. National Institutes of Health; 2002.
20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
21. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization; 2011.
22. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29.
23. Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.
24. Chamberland JP, Berman RL, Aronis KN, Mantzoros CS. Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation, and lacks day/night variation in humans. Eur J Endocrinol. 2013;169:453-462.
25. Wang X, Guo J, Wu Q, et al. Chemerin/chemR23 association with endothelial-mesenchymal transition in diabetic nephropathy. Int J Clin Exp Pathol. 2017;10:7408-7416.
26. De Palma G, Castellano G, Del Prete A, et al. The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int. 2011;79:1228-1235.
27. Vermi W, Riboldi E, Wittamer V, et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med. 2005;201:509-515.
28. Garland JS. Elevated body mass index as a risk factor for chronic kidney disease: current perspectives. Diabetes Metab Syndr Obes. 2014;7:347-355.
29. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159-166.
30. Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161:339-344.
31. Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997;51:1980-1985.
32. Risch L, Saely C, Hoefle G, et al. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin Chim Acta. 2007;376:108-113.
33. Stein S, Bachmann A, Lössner U, et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care. 2009;32:126-128.
34. Alcelik A, Tosun M, Ozlu MF, et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res. 2012;35:511-516.
35. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity. 2007;15:1617-1622.
36. Rhee CM, Nguyen DV, Moradi H, et al. Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kidney Dis. 2015;66:313-321.